S5 - E9.1 - VCTE As A Prognostic And Therapeutic Tool For MASLD
Send us Fan Mail This conversation focuses on the role of VCTE in diagnosing, staging and treating MASLD patients, both in terms of prognostic ability of VCTE when compared to biopsy and separately as...
6 Apr 20249min
S5 - E9 - Value of VCTE Or Other In-Office MASLD Monitoring
Send us Fan Mail Hannes Hagstrom joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss recent research panelists have conducted. This content-dense conversation focuses initially on the ...
4 Apr 202453min
S5 - E8 - Changing Patient Incentives For Participating In MASH Clinical Trials
Send us Fan Mail With Louise Campbell and Jörn Schattenberg both on Easter Week vacations, Fatty Liver Alliance Founder Mike Betel joins Roger Green to continue a brief conversation they began in a po...
1 Apr 202415min
S5 - E7.6 - MASLD Patient Advocates' Recommendations for Others after Rezdiffra Approval
Send us Fan Mail So far, this conversation has focused on Rezdiffra approval and its many forms of impact on MASLD patient advocates. This conversation considers their recommendation for others. The...
24 Mar 20249min
S5 - E7.5 - Will Increasing the Focus on MASH via Rezdiffra Overwhelm the Healthcare System?
Send us Fan Mail This conversation asks what impact Rezdiffra patient education might have on a U.S. healthcare system in which 38% of American adults live with some form of MASLD and 15% live with MA...
24 Mar 202411min
S5 - E7.4 - How MASH patient advocates plan to support Rezdiffra
Send us Fan Mail This conversation focuses on how the role of MASLD patient advocates might change and expand in the aftermath of Rezdiffra being approved. To Wayne Eskridge, this “raises an entire...
24 Mar 202411min
S5 - E7.3 - Patient advocacy and the Rezdiffra label
Send us Fan Mail This conversation focuses on the steps that patient advocates took to educate the FDA on what patients wanted in a MASH drug label, in this case for Rezdiffra. It starts with Jeff M...
23 Mar 202410min
S5 - E7.1 - Rezdiffra is approved! How patient and their advocates processed the news about the first MASH drug
Send us Fan Mail This conversation focuses on advocates' reactions throughout the day on Thursday, March 14, the day Rezdiffra became the first MASH drug approved in the U.S. Specifically, panelists...
23 Mar 202413min
